September 29, 2026
1 min read

NorthStar locks down $185M as radiopharmaceutical isotope, CDMO expansion plans advance

Bookended by its first commercial-scale manufacturing of the radioisotope actinium-225 in January and an expected high-capacity production line launch by the end of the year, radiopharmaceutical supplier and CDMO NorthStar Medical Technologies has secured a hefty chunk of change to pave the way for long-term success.

Leave a Reply

Your email address will not be published.

Previous Story

STAT+: Overton won’t get a vote before midterms

Next Story

5 Things to Help Make Life With Rett Syndrome More Manageable

Previous Story

STAT+: Overton won’t get a vote before midterms

Next Story

5 Things to Help Make Life With Rett Syndrome More Manageable

Latest from Blog

Top health takeaways from the midterm elections

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning from a round-the-clock elections team at STAT, where we’ve been closely monitoring
Go toTop